Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Sweden flag Sweden · Delayed Price · Currency is SEK
299.20
+2.60 (0.88%)
May 6, 2025, 2:00 PM CET
6.86%
Market Cap 101.87B
Revenue (ttm) 26.24B
Net Income (ttm) 3.96B
Shares Out 343.46M
EPS (ttm) 11.43
PE Ratio 25.96
Forward PE 20.16
Dividend n/a
Ex-Dividend Date n/a
Volume 34,575
Average Volume 335,609
Open 295.20
Previous Close 296.60
Day's Range 295.00 - 299.20
52-Week Range 241.80 - 354.40
Beta 0.26
RSI 61.80
Earnings Date Jul 16, 2025

About STO:SOBI

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy... [Read more]

Sector Healthcare
Founded 1939
Employees 1,806
Stock Exchange Nasdaq Stockholm
Ticker Symbol SOBI
Full Company Profile

Financial Performance

In 2024, STO:SOBI's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial Statements

News

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

STOCKHOLM , April 1, 2025 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be ...

5 weeks ago - PRNewsWire

Swedish Orphan Biovitrum targets high single-digit growth in 2025 amid robust pipeline advancements

Earnings Call Insights: Swedish Orphan Biovitrum (OTCPK:BIOVF) Q4 2024Management ViewCEO Guido Oelkers highlighted an 8% growth in Q4 revenues, driven...

3 months ago - Seeking Alpha

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

STOCKHOLM , Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"),...

6 months ago - PRNewsWire

Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases

Swedish Orphan Biovitrum AB (Sobi) (OTC: SWOBY) (OTC: BIOVF) and Apellis Pharmaceuticals, Inc . (NASDAQ: APLS) on Thursday released topline data results from Phase 3 VALIANT study of systemic pegce...

9 months ago - Benzinga

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2024 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2024 Earnings Conference Call July 16, 2024 8:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financi...

10 months ago - Seeking Alpha

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript

1 year ago - Seeking Alpha

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

STOCKHOLM , April 4, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be ...

1 year ago - PRNewsWire

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)

STOCKHOLM , Nov. 30, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) ("Sobi") has, as previously announced, carried out a share issue of series C shares, which has resulted...

1 year ago - PRNewsWire

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2023 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)

STOCKHOLM, Sweden , Aug. 15, 2023 /PRNewswire/ -- The Sobi® EGM was convened today on 15 August 2023. At the EGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Au...

1 year ago - PRNewsWire

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2023 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2023 Results Conference Call July 18, 2023 7:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financia...

1 year ago - Seeking Alpha

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

STOCKHOLM , July 18, 2023 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"),...

1 year ago - PRNewsWire

New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

STOCKHOLM , June 30, 2023 /PRNewswire/ -- As per 30 June 2023, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 311,336,796 shares. All shares are common shares.

2 years ago - PRNewsWire

Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing

XTEND-Kids data confirms the efficacy and safety profile of efanesoctocog alfa with 50 IU/kg dosing in previously treated children as already shown in adults and adolescents. Factor VIII inhibitor dev...

2 years ago - PRNewsWire

CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.

Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio.

2 years ago - Barrons

CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings

CTI BioPharma Corp. CTIC stock soared 83% in premarket trading after Swedish Orphan Biovitrum AB SE:SOBI said it had entered into an agreement to acquire the biotech in a deal valued at $1.7 billion. ...

2 years ago - Market Watch

Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion

Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a deal valued at $1.7 billion. The Stockholm-based dr...

2 years ago - Market Watch

Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTIO...

2 years ago - PRNewsWire

Sobi to Acquire CTI BioPharma

Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE , May 10, 2023 /PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) ("CTI"), a commer...

2 years ago - PRNewsWire